In vivo thrombosis after deep arterial injury has been experimentally shown by receptor inhibitors to be mediated predominantly by thrombin activation of platelets and to a lesser extent by thrombin-related fibrin formation. Thrombosis and thrombolysis are dynamic and simultaneous processes that may influence each other, depending on the exposure and concentration of thrombin and administered agents and dosages. The dose-dependent antithrombotic effect of heparin is mediated by its antithrombin action, but is incomplete even at dosages of 500 units/kg administered over 1 hour.1"2
Because of the critical role of thrombin in the thrombotic and lytic processes and the improved inhibition of thrombin in all locations by small molecular and specific thrombin inhibitors, the articles concerning the specific thrombin inhibitors hirudin and argatroban in the previous3 and the present4 issues of Circulation are of interest. Haskel Although thromboxane is a stronger agonist than serotonin or ADP, the three are synthesized and secreted secondarily by the platelet after initial activation by thrombin, collagen, or both.9 Thus, in the context of acute arterial thrombosis, an evolving priority is the search for agents that block the interaction of thrombin, collagen, or both with platelets.
Factors That Modulate Arterial Thrombosis and
Antithrombotic Efficacy The etiology and pathogenesis of arterial thrombosis relate to 1) the vascular substrate for thrombus formation (subendothelium, media or ruptured plaque, prosthetic material, or residual thrombus), 2) rheology of blood flow (high-flow disturbance by stenosis or branching increases platelet deposition, while stasis favors fibrin formation), and 3) the systemic hemostatic-thrombotic state (levels of catecholamines and of various lipoproteins, coagulation, and other factors).10l" Thus, these factors relate to the overall thrombogenicity and dictate the types and potency of therapy required for treatment.1' Arterial thrombi are by nature predominantly platelet-rich, with a fibrin-rich tail, but even these may differ in etiology, size and type, and potency of therapy required. Thus, experimentally, arterial thrombi after mild endothelial and subendothelial injury (low thrombogenicity by substrate) are not macroscopic or obstructive (unless associated with stenosis), are not well-anchored and are easily washed away, and can be prevented by aspirin.12-14 Thrombi after deep damage or injury into the media (high thrombogenicity by substrate) are macroscopic and partially (or totally) obstructive, are well-anchored and mimic thrombi associated with plaque rupture (thrombogenic collagen types I and III or exposure of tissue factor), are reduced to 25-30% of control size but not prevented by aspirin, and are totally eliminated by potent specific thrombin inhibition with hirudin or intra-arterial argatroban.1 '5,6 Arterial thrombi associated with prosthetic material such as metal stents are often totally obstructive, have many more associated thrombi if there is predeployment arterial angioplasty and injury, and are not prevented by heparin, aspirin, and dipyridamole or by usual doses of hirudin.15 These thrombi probably require higher-dose antithrombin therapy be- The Role of Antithrombins In the report by Haskel et al,3 the specific antithrombin hirudin significantly enhanced thrombolysis and totally prevented reocclusion. The response to hirudin was both therapeutic and diagnostic of the thrombin-dependent mechanism of arterial reocclusion. Hirudin is highly specific, potent, and nearly irreversibly (KD=10 15 M) binds thrombin in a 1:1 complex.23 Thus, the blood level of hirudin required for total prevention of thrombosis appears to be an in vivo index of the thrombin content of the thrombotic state or lesion. For example, the blood level of hirudin necessary to inhibit formation of platelet thrombi is fivefold that required to inhibit formation of fibrin thrombi during disseminated intravascular coagulation.23 Hirudin levels eight to ten times higher are required to prevent thrombus formation on deeply injured compared with mildly injured arteries, and the differential is even greater for venous compared with arterial thrombi.'123,24 Thus, different doses of specific thrombin inhibitors appear to be necessary for different types of thrombosis. This may have implications for comparison of models of thrombosis and lysis, especially in view of these dynamic processes. Therefore, a description of the stimulus for thrombosis and the depth and extent of arterial injury is important for comparison of results between different laboratories. Moreover, differences between platelet inhibitors and antithrombin therapies may be less apparent in thrombi of lower index of thrombin content and may be greater for the prevention of reocclusion when the index of thrombin content appears to be high.
A synthetic, reversible thrombin inhibitor with lower binding affinity (KD= 10-9 M), argatroban, reduces but does not eliminate platelet-rich thrombosis in the everted rabbit femoral artery unless administered intra-arterially.6 It also accelerates thrombolysis, reduces reocclusion after thrombolysis when combined with aspirin, and is experimentally superior to heparin in reducing thrombosis. [5] [6] [7] In this issue of Circulation, Clarke et a14 report the first phase I study with argatroban in the United States. As with hirudin and argatroban administration in animals,525 there was dose-dependent prolongation of the activated partial thromboplastin time in humans. The thrombin time will probably be too sensitive for monitoring optimal antithrombin doses for prevention of arterial thrombosis.25 Future doseresponse studies of argatroban alone in arterial thrombosis might show that increased doses may be useful and obviate the need for simultaneous aspirin administration. This possibility is suggested by studies with hirudin25 and intra-arterial argatroban.6 However, the lower binding affinity of argatroban compared with that of hirudin may not permit this comparable possibility.
Never before have we had therapy for total prevention of arterial thrombosis. However, we do not know the appropriate dose and duration of therapy needed to prevent later thrombosis or, in cases of preexisting thrombus, to complete endogenous lysis (theoretically possible when thrombosis is totally blocked) and prevent thrombosis in animals or humans. To ensure patient safety, to promote intelligent and cost-saving clinical trials, and to minimize future drug cost, doseresponse analyses and studies of the duration of antithrombotic efficacy of specific thrombin inhibition alone (initially with aspirin to be safe and practical) need to be completed before combining this potent therapy with a lytic agent in humans.
